Self-Adhering Magnetic Device to Treat Corneal Exposure

计划入组 25 人 · 首次发布于 2024 年 3 月 4 日

Adhering to Dietary Approaches for Personal Taste (ADAPT)

计划入组 3,001 人 · 首次发布于 2017 年 7 月 24 日

Adherus™ Dural Sealant in Spinal Procedures

计划入组 114 人 · 首次发布于 2020 年 8 月 4 日

Friedreich's ataxia therapy (Adverum Biotechnologies)

Melatonin oral gel(Spherium Biomed SL)

AAV.7M8/LSV1 GTx (Adverum Biotechnologies)

ADVERUM BIOTECHNOLOGIES INC.

United States

Smart Drug Delivery Systems Market Poised for 17% Growth as Chronic Disease Management Evolves

Adverum's Ixo-vec Shows Promise in Wet AMD Phase 2 Trial, Phase 3 Planned for 2025

Lilly Acquires Adverum Biotechnologies for $262M to Advance Gene Therapy for Wet AMD